Table 2.

CTC Grade 3 and 4 adverse events that occurred during the course of TMZ that was administered concomitantly with radiotherapy

	Adverse event	≥ 65 (n = 27)		< 65 (n = 49)		p value
		N	%	N	%
Hematologic	Leukocytopenia	6 (2)	22 (7)	6 (1)	12 (2)	0.33
	Neutropenia	6 (3)	22 (11)	4	8	0.15
	Lymphocytopenia	7 (3)	26 (11)	26 (3)	53 (6)	0.03*
	Thrombocytopenia	3 (3)	11 (11)	0	0	0.042*
	Overall Grade 3/4	10	37	26	53	0.23
	Overall Grade 4	7	26	4	8	0.046*
Treatment-related nonhematologic	Constipation	0	0	1	2	1.0
	Fatigue	1	4	1	2	1.0
	Pneumonia	1	2	1	2	1.0
	Liver enzyme	3	11	2	4	0.34
	Hypoalbuminemia	1	4	0	0	0.35
	Rash	0	0	1	2	1.0
	Meningitis	1	4	0	0	0.35
	Cognitive dysfunction	3	11	0	0	0.042*
	Overall Grade 3/4	8	30	6	12	0.072

Figures in parentheses show the number or percentage of Grade 4 adverse events.

^*Significant value. CTC: common toxicity criteria, TMZ: temozolomide.